For researchers hunting new treatments for Alzheimer's and Parkinson's, the path from a promising compound to a viable drug candidate is a costly, slow-motion gamble. Standard assays can tell you if a molecule binds to a target, but they often fail to reveal how it truly behaves inside a living neuron over time. A Brisbane startup, Accretion Bio, is betting that a nanoscale view of this process can de-risk the earliest, most expensive stages of drug development [Phys.org, October 2026].
The NASTIC wedge
The company's core technology is NASTIC, short for Nanoscale Spatiotemporal Indexing Clustering. It is a live-cell imaging platform that combines wet-lab techniques with computational analysis to track individual proteins moving and interacting inside living cells [Phys.org, October 2026]. The claimed differentiation is resolution and context. Where conventional methods might offer a static snapshot or a population average, NASTIC is designed to generate functional, mechanism-of-action data at the single-molecule level, across both space and time [Phys.org, October 2026]. For neurodegenerative disease research, this means watching how proteins implicated in conditions like Alzheimer's actually behave in a living neuron before, during, and after exposure to a potential therapeutic compound.
An academic engine in Brisbane
Accretion Bio is a classic academic spinout, with its technological roots firmly planted at the University of Queensland's Queensland Brain Institute (QBI). The founding team pairs a commercial operator with the scientists who built the tool. CEO Phillip Craig, who has a background in biotech commercialization and venture creation, leads the company [Phill Craig’s LinkedIn profile]. The platform's inventors, Professor Yann Meunier and Dr. Tristan Wallis, serve as technology co-founders [Phys.org, October 2026]. Their lab at QBI investigates synaptic transmission and neurodegeneration using advanced microscopy, providing the foundational research NASTIC commercializes [Neuronal trafficking - Queensland Brain Institute - University of Queensland, retrieved 2026]. This origin gives the startup a credible, deep-tech foundation, though its commercial path is just beginning.
The company's initial strategy is twofold. First, it is building internal drug-discovery programs focused on neurodegenerative diseases [Phys.org, October 2026]. Second, and more immediately relevant for its business model, it plans to work with pharmaceutical and biotechnology partners, offering NASTIC as a platform to generate earlier, more mechanistic readouts for their own discovery pipelines [Phys.org, October 2026]. The company has attracted backing from global venture firm Antler, though the amount of its 2026 seed round remains undisclosed [Phys.org, October 2026].
The long road to validation
The ambition is clear, but the runway is long and the risks are inherent to the field. Accretion Bio is operating at the intersection of two famously difficult arenas: cutting-edge scientific tools and neurodegenerative drug discovery. The platform's ultimate value will be determined not by its technical specifications, but by its ability to consistently produce data that changes development decisions in a meaningful way. This requires rigorous validation against known outcomes and, eventually, peer-reviewed publications demonstrating its predictive power. Furthermore, while the platform may have applications in immunology and oncology, the company's initial focus on neurodegeneration means its fate is tied to one of the most challenging therapeutic areas, with a history of costly late-stage failures [Phys.org, October 2026].
The company's near-term milestones will be closely watched. Key signals will include:
- Scientific validation. The first peer-reviewed studies demonstrating NASTIC's utility in a drug-discovery context.
- Partner traction. Signed collaborations with named pharmaceutical or biotech firms, moving beyond reported interest.
- Pipeline progress. Concrete milestones from its own internal drug programs, which will require significant additional capital to advance.
For the millions of patients and families waiting for breakthroughs in Alzheimer's and Parkinson's, the standard of care today remains largely focused on managing symptoms, not altering the disease's progression. New therapeutic approaches have been scarce and incremental. Tools like NASTIC represent a bet on a different kind of progress: that by seeing the biological drama of neurodegeneration play out in real time, at the molecular level, researchers can make smarter, faster bets on which compounds are worth pursuing. It is a high-stakes, long-term wager on the power of basic neuroscience to finally translate into clinical wins.
Sources
- [Phys.org, October 2026] Nanoscale tech tracks proteins inside living neurons to guide Alzheimer's and Parkinson's drug discovery | https://phys.org/news/2026-10-nanoscale-tech-tracks-proteins-neurons.html
- [Phill Craig’s LinkedIn profile] Phillip Craig's profile | https://www.linkedin.com/in/phill-craig-3a2b3a1a/
- [Neuronal trafficking - Queensland Brain Institute - University of Queensland, retrieved 2026] Meunier lab research focus | https://qbi.uq.edu.au/meuniergroup
- [The University of Queensland, 2026] UQ technology opens new front in Alzheimer’s and Parkinson’s drug discovery | https://news.uq.edu.au/2026-10-uq-technology-opens-new-front-alzheimers-and-parkinsons-drug-discovery